PATENT CLAIM ANALYSIS

Application Number: 16053217
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-07
Patent Classification: ["514", "017900"]

Abstract:
The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically.

Claim (Index 15):
The method of  claim 12 , wherein the decrease in the rate of progression of multiple sclerosis is a decrease in the rate of development of neurological impairment in the subject.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 96.0
- Lexical Diversity: 1.80488
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13848811', '12456883', '13443981', '15541944', '09952532']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7206711089509867
- 35 USC 102 Novelty (BERT): 0.512109895771119
- Combined Prediction Score: 0.699814987633
- Mean Citation Score: 216.985012
- Max Citation Score: 240.76187
- Similarity Product: 145.4205789866024

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test